AL-ADTRAN
13.3.2023 14:01:39 CET | Business Wire | Press release
Adtran®, Inc., (NASDAQ:ADTN), the leading provider of next-generation open and disaggregated networking solutions, and Satelles, Inc., the leading supplier of secure time and location technology using low-earth orbit (LEO) satellites, today announced a strategic partnership. The collaboration will enable operators of critical infrastructure to safeguard their timing networks with Satellite Time and Location (STL) technology. By integrating Satelles’ STL into its Oscilloquartz network synchronization products, Adtran will provide an alternative to GNSS systems or a way to augment them with enhanced reliability and security. With the ability to deliver highly precise PNT service, even in GNSS-denied applications, STL offers a vital resource for mobile operators, power utility companies, government, scientific research and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005475/en/
Adtran’s partnership with Satelles will further strengthen its aPNT+™ solution. (Photo: Business Wire)
“We’re pleased to be working with Adtran’s Oscilloquartz division to integrate STL into its portfolio of PTP network timing devices. Together, we’re enabling even more customers to benefit from their game-changing aPNT+™ technology,” said Christina Riley, VP and GM of commercial enterprise solutions at Satelles. “Leveraging LEO signals that are 1,000 times stronger than GNSS, our STL solution is transforming the PNT industry. It’s ideal for providing accurate, reliable timing where GNSS can’t reach, such as indoor locations. And in settings where it is possible to receive GNSS signals, STL complements it with additional PNT services to improve resiliency. Easy and affordable to install, STL also offers new levels of security for synchronization network infrastructure.“
STL provides augmented and secure backup for GPS or other GNSS by harnessing encrypted signals transmitted via LEO satellites. It ensures timing and location information that is highly precise, robustly secure, and accessible worldwide. STL is effectively impervious to cyberattacks and is far less susceptible to GNSS vulnerabilities such as signal disruption and manipulation. And because STL signals are up to 1,000 times stronger than GNSS, they can easily reach into buildings and other hard-to-reach locations. Through its partnership with Satelles, Adtran’s Oscilloquartz division will incorporate these benefits into its end-to-end timing toolkit. What’s more, as well as integrating STL into its grandmaster clocks, it will develop miniature M.2 form factor STL receiver modules for third-party product integration.
“We’re excited to offer Satelles’ innovative STL technology as the perfect addition to our portfolio. Reliable, precise and secure, STL is an excellent source of alternative PNT services that’s ideal for use in situations where distributed PTP is unavailable. It also creates new market opportunities for indoor 5G and data center use cases. By incorporating it into our solutions, we’ll empower operators of mission-critical networks to bring robust timing to the most challenging environments and remove the expense of installing outdoor antennas and coring through concrete,” commented Gil Biran, GM of Oscilloquartz, Adtran. “This partnership reinforces our commitment to providing the most advanced and reliable network timing solutions available, and we look forward to bringing the advantages of STL to customers around the world.”
About Adtran
Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. Adtran, Inc. is a wholly-owned subsidiary of ADTRAN Holdings, Inc. (NASDAQ:ADTN and FSE: QH9). Find more at Adtran, LinkedIn and Twitter.
About Satelles
Satelles protects critical infrastructure by providing STL as an alternative positioning, navigation, and timing (PNT) technology that delivers stability, reliability, and trust required by commercial enterprises and government entities. STL’s secure signal from low Earth orbit (LEO) is resilient to regional outages of GPS and other GNSS. Customers turn to Satelles for a primary source of PNT, and STL also safeguards against devastating attacks to GPS/GNSS capable of disrupting or disabling electrical grids, wireless communications networks, financial systems, and other private and public infrastructure. Built on a foundation of expertise in the public sector, Satelles delivers first-to-market proven technology that is sold commercially throughout the world today. Learn more at www.satelles.com.
Published by
Adtran, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005475/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
